Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Allergy Année : 2021

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

Cristoforo Incorvaia
Mona Al-Ahmad
  • Fonction : Auteur
Ignacio Ansotegui
  • Fonction : Auteur
Stefania Arasi
Claus Bachert
Catherine Bos
  • Fonction : Auteur
Jean Bousquet
  • Fonction : Auteur
Andrzéj Bozek
Davide Caimmi
Moises Calderón
  • Fonction : Auteur
Thomas Casale
  • Fonction : Auteur
Adnan Custovic
  • Fonction : Auteur
Frédéric De Blay
  • Fonction : Auteur
Alain Didier
Alessandro Fiocchi
Adam Fox
  • Fonction : Auteur
Philippe Gevaert
  • Fonction : Auteur
Maximiliano Gomez
  • Fonction : Auteur
Enrico Heffler
Natalia Ilina
  • Fonction : Auteur
Carla Irani
  • Fonction : Auteur
Marek Jutel
  • Fonction : Auteur
Efstrathios Karagiannis
  • Fonction : Auteur
Ludger Klimek
  • Fonction : Auteur
Piotr Kuna
  • Fonction : Auteur
Robin O'Hehir
  • Fonction : Auteur
Oxana Kurbacheva
  • Fonction : Auteur
Paolo Matricardi
Mario Morais-Almeida
Ralph Mosges
Natalija Novak
  • Fonction : Auteur
Yoshitaka Okamoto
  • Fonction : Auteur
Petr Panzner
Nikolaos Papadopoulos
Hae‐sim Park
Giovanni Passalacqua
Ruby Pawankar
  • Fonction : Auteur
Oliver Pfaar
Peter Schmid-Grendelmeier
Silvia Scurati
  • Fonction : Auteur
Miguel Tortajada-Girbés
  • Fonction : Auteur
Carmen Vidal
J. Christian Virchow
Ulrich Wahn
Margitta Worm
Petra Zieglmayer
  • Fonction : Auteur
Giorgio Canonica
  • Fonction : Auteur

Résumé

Abstract The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single‐allergen molecules and to distinguish the causative molecules from those merely cross‐reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi‐genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.

Dates et versions

hal-04260772 , version 1 (26-10-2023)

Identifiants

Citer

Cristoforo Incorvaia, Mona Al-Ahmad, Ignacio Ansotegui, Stefania Arasi, Claus Bachert, et al.. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy, 2021, 76 (4), pp.1041-1052. ⟨10.1111/all.14575⟩. ⟨hal-04260772⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More